Literature DB >> 18036396

Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses.

Jana Paderova1, Marija Orlic-Milacic, Maisa Yoshimoto, Gilda da Cunha Santos, Brenda Gallie, Jeremy A Squire.   

Abstract

Gain of the short arm of chromosome 6, usually through isochromosome 6p formation, is present in approximately 50% of retinoblastoma tumors. The minimal region of gain maps to chromosome band 6p22. Two genes, DEK and E2F3, are implicated as candidate oncogenes. However, chromosomal translocations have been overlooked as a potential mechanism of activation of oncogenes at 6p22 in retinoblastoma. Here, we report combined spectral karyotyping), 4',6-diamidino-2-phenylindole banding, mBAND, and locus-specific fluorescence in situ hybridization analyses of four retinoblastoma cell lines, RB1021, RB247c, RB383, and Y79. In RB1021 and RB247c, 6p undergoes structural rearrangements involving a common translocation breakpoint at 6p22. These data imply that 6p translocations may represent another mechanism of activation of 6p oncogene(s) in a subset of retinoblastomas, besides the copy number increase. In addition to 6p22, other recurrent translocation breakpoints identified in this study are 4p16, 11p15, 17q21.3, and 20q13. Common regions of gain map to chromosomal arms 1q, 2p, 6p, 17q, and 21q.

Entities:  

Mesh:

Year:  2007        PMID: 18036396     DOI: 10.1016/j.cancergencyto.2007.08.014

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

Review 1.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Authors:  J Martinez-Useros; I Moreno; M J Fernandez-Aceñero; M Rodriguez-Remirez; A Borrero-Palacios; A Cebrian; T Gomez Del Pulgar; L Del Puerto-Nevado; W Li; A Puime-Otin; N Perez; M S Soengas; J Garcia-Foncillas
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

3.  Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Authors:  Dong-Mei Wang; Ling Liu; Lei Fan; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2012-10-10       Impact factor: 4.742

4.  TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.

Authors:  Sounak Gupta; Sarah H Johnson; George Vasmatzis; Binu Porath; Jeannette G Rustin; Priya Rao; Brian A Costello; Bradley C Leibovich; R Houston Thompson; John C Cheville; William R Sukov
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

Review 5.  The genomic landscape of retinoblastoma: a review.

Authors:  Brigitte L Thériault; Helen Dimaras; Brenda L Gallie; Timothy W Corson
Journal:  Clin Exp Ophthalmol       Date:  2013-05-22       Impact factor: 4.207

6.  DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.

Authors:  Junying Wang; Limei Sun; Mingyue Yang; Wenting Luo; Ying Gao; Zihui Liu; Xueshan Qiu; Enhua Wang
Journal:  J Histochem Cytochem       Date:  2013-04-09       Impact factor: 2.479

7.  RUNX2 (6p21.1) amplification in osteosarcoma.

Authors:  Sounak Gupta; Tatsuo Ito; Deepu Alex; Chad M Vanderbilt; Jason C Chang; Nasrin Islamdoust; Yanming Zhang; Khedoudja Nafa; John Healey; Marc Ladanyi; Meera R Hameed
Journal:  Hum Pathol       Date:  2019-10-25       Impact factor: 3.466

8.  DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.

Authors:  Javier Martinez-Useros; Maria Rodriguez-Remirez; Aurea Borrero-Palacios; Irene Moreno; Arancha Cebrian; Teresa Gomez del Pulgar; Laura del Puerto-Nevado; Ricardo Vega-Bravo; Alberto Puime-Otin; Nuria Perez; Sandra Zazo; Clara Senin; Maria J Fernandez-Aceñero; Maria S Soengas; Federico Rojo; Jesus Garcia-Foncillas
Journal:  BMC Cancer       Date:  2014-12-16       Impact factor: 4.430

9.  DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.

Authors:  Lijuan Lin; Junjie Piao; Wenbin Gao; Yingshi Piao; Guang Jin; Yue Ma; Jinzi Li; Zhenhua Lin
Journal:  BMC Cancer       Date:  2013-07-31       Impact factor: 4.430

10.  A Meta-Analysis of Retinoblastoma Copy Numbers Refines the List of Possible Driver Genes Involved in Tumor Progression.

Authors:  Irsan E Kooi; Berber M Mol; Maarten P G Massink; Marcus C de Jong; Pim de Graaf; Paul van der Valk; Hanne Meijers-Heijboer; Gertjan J L Kaspers; Annette C Moll; Hein Te Riele; Jacqueline Cloos; Josephine C Dorsman
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.